Ovarian cancer is the seventh most commonly diagnosed disease worldwide as well as the eighth most lethal disease among females around the world[@b1]. After primary treatment including staging or debulking surgery and platinum-based adjuvant chemotherapy, around half of patients will relapse within 16 months[@b2]. Thus, effective clinic-pathological biomarkers are urgently required.

Epidemiological studies have indicated the potential role of steroid hormone in the etiology of ovarian cancer[@b2]. Hormone receptors, including estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), follicle-stimulating hormone receptor (FSHR), luteinizing hormone receptor (LHR) and gonadotropin-releasing receptor (GnRHR), could mediate the effects of steroid hormones on ovarian cancer development and progression[@b3][@b4][@b5][@b6][@b7]. Previous studies have shown that ER and PR expression could be prognostic biomarkers of ovarian cancer. However, these results are inconsistent and sometimes contradictory[@b8][@b9][@b10][@b11][@b12]. Studies that describe the associations between AR, FSH-R, LH-R, and GnRHR expression and ovarian cancer survival are relatively sparse[@b7][@b12][@b13][@b14][@b15].

In addition, epithelial ovarian cancers are a group of heterogeneous tumors based on distinctive morphological and molecular genetic features[@b16]. As mentioned above, most studies combined all of the disease subtypes and had small sample sizes. This may hinder efforts to identify the subtype-specific significance of hormone receptor expression. Some conflicting data are difficult to interpret[@b8][@b9][@b10][@b11]. Additionally, because the vast majority of ovarian cancers are HGSCs, meaningful and reliable indicators for further classifying this large group of patients are needed.

We analyzed the expression levels of hormone receptors according to the hypothalamic-pituitary-gonadal axis and another two potentially useful biomarkers (HER2 and Ki67) in 875 patients with HGSC. A new hormone receptor-based classification of HGSC was established, and patients were divided into five subgroups with distinctive clinical features.

Methods
=======

Clinical Data
-------------

The clinical data were collected retrospectively from women who underwent primary surgery for HGSC at our hospital between April, 2005 and June, 2013. This study was conducted according to the Declaration of Helsinki and was approved by the Committee at Fudan University Shanghai Cancer Center. All participants provided written informed consent. Patients were excluded if they had received neoadjuvant chemo therapy, had been treated for recurrent disease, or were found to have other histological diagnoses on pathological review.

Clinical and pathological data were obtained from the medical records, cancer registries, and pathology reports. Patient characteristics, including age, menopausal status, FIGO stage, surgical outcomes, date of progression or recurrence, and the patient's disease status at last contact, were collected. All patients were followed up until December 31, 2014.

R0 was defined as no macroscopic residual disease (RD) after surgery. Platinum sensitivity was defined as a time interval of 6 months or longer between the completion of platinum-based chemotherapy and the detection of relapse. Platinum resistance was defined as disease progression during adjuvant chemotherapy or within the 6-month interval between the completion of chemotherapy and disease relapse.

Progression-free survival (PFS) was defined as the time interval from the date of primary surgery to the date of disease progression or recurrence. Overall survival (OS) was defined as the time interval from the date of the primary surgery to the date of death or the last follow-up.

Tissue Microarray and Immunohistochemistry
------------------------------------------

The histological diagnoses were based on the WHO criteria[@b17]. The samples were re-reviewed and reclassified as low and high-grade serous carcinoma based on the two-tiered grading system by two experienced gynecological pathologists (two co-authors of this paper). A microarray (1 mm) with triplicate tissue samples from each tumor was prepared[@b9][@b18]. Immunohistochemical staining was performed for ER, PR, HER2 and Ki-67 using a Ventana Benchmark XT autostainer (Ventana Medical Systems Inc., Tucson, AZ, USA). Staining for AR, FSHR, LHR and GnRHR was performed using the Envision horseradish peroxidase system (DAKO EnVision System K5007) following the manufacturer's protocol. The following primary antibodies were used: ER (Roche SP1), PR (Roche 1E2), AR (Abcam ab133273, 1:100), FSH-R (Abcam ab150557, 1:100), LH-R (Santa Cruz sc-25828, 1:40), GnRH-R (Abcam ab183079, 1:50), HER2 (Roche 4B5), and Ki67 (Roche 30--9).

The results were independently judged, evaluated, and scored by two experienced gynecological pathologists without knowledge of the patients' information. The results were recorded as the numerical mean of the values obtained from the triplicate cores. The intra-class correlation coefficient (ICC) was calculated to evaluate the internal consistency of the immunoscore of the three cores from each individual tumor sample. The Cronbach's α indexes were approximately 0.9, which meant that there were no differences in parameter expression among the different morphological tissues. The expression levels of hormone receptors were determined using the following criteria:

ER, PR and AR levels: \>10% showing positive nuclear staining of any intensity was defined as positive[@b19][@b20].

FSH-R and LH-R levels: Evaluation of the cytoplasmic staining reaction was performed in accordance with the immunoreactive score (IRS). The IRS was defined as staining intensity (SI) by the percentage of positive cells (PP). SI was defined as 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). PP was defined as 0 (negative), 1 (no more than 10% positive cells), 2 (11% to 50% positive cells), 3 (51% to 80% positive cells) and 4 (more than 80% positive cells). IRS = SI × PP, IRS ≥ 3 was defined as positive[@b21].

GnRHR level: The cytoplasmic staining of GnRHR was recorded as negative, weak, moderate and strong. Staining of any intensity was regarded as positive[@b22].

HER2 level: Membrane HER2 staining was recorded by scores of 0, 1+, 2+ and 3+ according to the ASCO/CAP guideline[@b23]. In our cohort, any score of \>0 (1+, 2+, and 3+), not only 3+, was regarded as positive.

Ki67 level: \>50% showing positive nuclear staining of any intensity was defined as positive, which could discriminate patients into groups with different prognoses[@b24].

Statistical Analyses
--------------------

SPSS software (version 21.0, IBM Inc, USA), R software (version 3.2, Mathsoft Inc, USA) and GraphPad Prism software (version 6.0, GraphPad software Inc, USA) were used for the statistical analyses. Descriptive statistics were summarized as the means with the standard deviations (SD), the medians with the interquartile ranges (IQRs) or ranges, or the frequencies with the percentages. The categorical data were compared with chi-square or Fisher's exact tests as appropriate. Logistic regression analysis was used in the multivariate analyses to evaluate the effects of the predictive factors, which are expressed as odds ratios (ORs). After the predictive and prognostic analyses, we identified ER, PR, AR and Ki67 as meaningful clinical indicators for HGSC molecular classification. An unsupervised hierarchical clustering analysis was performed to identify which tumors were related to each other according to their expression regardless of other patient characteristics. And average linkage clustering was used based on the positive and negative expression values. The PFS and OS were analyzed with the Kaplan-Meier method and log-rank tests in the univariate analyses, and cox regression analysis was used in the multivariate analyses to evaluate the effects of the prognostic factors, which are expressed as hazard ratios (HRs). All patients were included in the OS analyses, however, 72 patients (8.2%) with missing data on recurrence were excluded from the PFS analyses. Among them, 24 patients could not recall their exact recurrence date, and 48 patients were recorded as died from cancer recurrence in the cancer registries but their relapse dates were not documented. P \< 0.05 was considered statistically significant, and all reported P values were 2-sided.

Results
=======

Patient characteristics and hormone receptor expression levels
--------------------------------------------------------------

The patient characteristics and hormone receptor expression levels are described in [Table 1](#t1){ref-type="table"}. Among the 875 patients, 602 of them (69%) were postmenopausal and 85 of them (10%) had a family history of breast or ovarian cancer. A total of 800 patients (91%) were of advanced stage (III--IV).

Because some cores in the TMA slides shed off during the procedure of IHC staining, only 863--868 patients had available expression data for each IHC parameter. Representative images of parameter staining are shown in [Figure S1](#S1){ref-type="supplementary-material"}. These parameters were present in the majority of HGSC patients. A total of 556 (64%) patients were ER positive. PR and AR were highly expressed in 13% and 36% of patients, respectively. Nearly 90% of patients were GnRHR positive; however, for HER2 staining, only 4% of patients were scored ≥1 (score 1+: 26 patients; score 2+: 3 patients; and score 3+: 2 patients, respectively). FSHR, LHR and Ki67 were highly expressed in 55%, 35% and 26% of the patients, respectively. The associations of these parameters are shown in [Table S1](#S1){ref-type="supplementary-material"}.

Independent analyses of hormone receptor expression levels
----------------------------------------------------------

All 875 patients in our study underwent primary staging or debulking surgery, and 272 (31%) of them were debulked to R0 after primary surgery. We did not observe any associations between residual disease and hormone receptor expression or expression of any other parameters ([Table S2](#S1){ref-type="supplementary-material"}).

A total of 849 (97%) patients had received platinum-based adjuvant chemotherapy following primary surgery. The majority of patients were administered taxanes (including paclitaxel (646/875, 74%), docetaxel (29/875, 8%)). A small number of patients received cyclophosphamide (18/875, 2%). Information regarding the combination of agents received by 23% (200/875) of the patients was not available. A total of 568 (67%) patients were platinum sensitive ([Table 1](#t1){ref-type="table"}). A greater proportion of the PR-positive (80.4% *vs.* 69.1%, p = 0.020) or AR-positive (76.2% *vs.* 67.3%, p = 0.010) patients were sensitive to platinum-based chemotherapy compared to the corresponding negative patients. Moreover, a larger proportion of patients with Ki67 over 50% were platinum sensitive compared to patients with Ki67 below 50% ([Table 2](#t2){ref-type="table"}). We did not observe any associations between platinum sensitivity and ER, FSHR, LHR, GnRHR or HER2 expression ([Table 2](#t2){ref-type="table"}). In the multivariate analysis, AR expression (OR = 0.625, 0.434--0.900, p = 0.011) and Ki67 over 50% (OR = 0.632, 0.429--0.931, p = 0.020) were independent predictors of platinum sensitivity ([Table S3](#S1){ref-type="supplementary-material"}).

The median follow-up time was 29 (1--115) months. A total of 499 (57.0%) patients had documented recurrence with a median (95% CI) PFS of 18 (16.8--19.2) months. The 2-year and 5-year PFSs were 38.1% and 19.4%, respectively. Among all of the patients in the study, 345 (39.4%) deaths were documented, and the median (95% CI) OS was 58 (51.4--64.6) months. The 2-year and 5-year OSs were 79.3% and 48.8%, respectively. The known negative influences on PFS or OS were confirmed and included advanced FIGO stage (p \< 0.001 and \< 0.001, respectively) and the presence of residual disease (p \< 0.001 and \<0.001, respectively).

In the univariate analyses of PFS, ER expression was associated with impaired PFS, while PR expression was associated with improved PFS (p = 0.036 and 0.009, respectively, [Figure S2](#S1){ref-type="supplementary-material"}, [Table 3](#t3){ref-type="table"}). The women with Ki67 over 50% tended to exhibit longer PFS than those with Ki67 below 50% (p = 0.021, [Figure S2](#S1){ref-type="supplementary-material"}, [Table 3](#t3){ref-type="table"}). The associations between AR, FSHR, LHR GnRHR or HER2 expression and PFS revealed no statistically significant differences. In the multivariate analysis with adjustments for age, FIGO stage, and cytoreduction outcome, ER (HR = 1.302, 1.077--1.573, p = 0.006) and PR (HR = 0.718, 0.538--0.958, p = 0.024) expression were found to be independent predictors of PFS ([Table 3](#t3){ref-type="table"}).

In the univariate analyses of OS, AR expression and Ki67 over 50% were associated with improved OS (p = 0.023 and 0.003, [Figure S3](#S1){ref-type="supplementary-material"}, [Table 3](#t3){ref-type="table"}). The women with positive PR expression tended to exhibit longer OS than those with negative PR expression; however, the difference was not significant (p = 0.061, [Figure S3](#S1){ref-type="supplementary-material"}, [Table 3](#t3){ref-type="table"}). The associations between FSHR, LHR, GnRHR or HER2 expression and OS revealed no statistically significant differences. In the multivariate analysis with adjustments for age, FIGO stage, and cytoreduction outcome, ER (HR = 1.288, 1.014--1.636, p = 0.038), AR (HR = 0.744, 0.578--0.959, p = 0.022) and Ki67 (HR = 0.688, 0.520--0.910, p = 0.009) expression were found to be independent predictors of OS. PR expression was no longer an independent predictor of OS (HR = 0.911, 0.617--1.346, p = 0.641, [Table 3](#t3){ref-type="table"}).

Molecular subtype classification of HGSC
----------------------------------------

Considering the predictive and prognostic analyses above, we identified ER, PR, AR and Ki67 as meaningful clinical indicators for HGSC molecular classification. A clustering analysis was performed to identify which tumors were related to each other according to ER, PR, AR and Ki67 expression. A total of five hormone receptor-based molecular subtypes were distinguished (PR+, PR − ER + AR+, PR − ER + AR−, PR − ER − AR+, and PR − ER − AR−). Ki67 did not play a dominant role in the classification ([Fig. 1A,B](#f1){ref-type="fig"}).

Characteristics of patients within each subgroup are shown in [Table 4](#t4){ref-type="table"}. Patients in the PR+ group were younger compared to those in the other groups (p \< 0.001). More patients were of advanced stage in the PR − ER + AR− group than in the other groups (p = 0.020). Patients in all subgroups received similar debulking surgery and adjuvant chemotherapy, and there was no difference in the surgery outcomes between the groups (p = 0.476). A greater proportion of patients were sensitive to platinum-based chemotherapy in the PR − ER − AR+ group compared with the other groups (p = 0.034).

The univariate Kaplan-Meier analysis for OS was performed ([Fig. 1C](#f1){ref-type="fig"}), and a statistically significant trend of increasing risk of death was observed among the subgroups (χ^2^ = 16.140, p \< 0.001, [Table 5](#t5){ref-type="table"}). In the multivariate analysis adjusted for age, FIGO stage and residual disease, patients also had orderly increased hazard ratios for death in the PR + (HR = 2.256, 0.983--5.175, p = 0.055), PR − ER + AR + (HR = 2.188, 1.004--4.796, p = 0.049), PR − ER − AR− (HR = 2.316, 1.097--5.082, p = 0.028) and PR − ER + AR− (HR = 2.928, 1.366--6.276, p = 0.006) subgroups compared with the PR − ER − AR+ subgroup ([Table 5](#t5){ref-type="table"}).

Discussion
==========

In this large mono-institutional study, six hormone receptors (ER, PR, AR, FSHR, LHR and GnRHR) and another two potentially useful biomarkers (HER2 and Ki67) were investigated. Based on the clustering expression patterns of four critical parameters (ER, PR, AR, and Ki67), we classified patients into five subgroups (PR+, PR − ER + AR+, PR − ER + AR−, PR − ER − AR+, and PR − ER − AR−) with distinctive clinic-pathological features.

Several studies have investigated the prognostic impact of hormone receptor expression in ovarian cancer. The majority of previous investigations focused on ER or PR expression levels, and these previous investigations obtained inconsistent results. Some studies implicated that ER or PR expression was associated with improved progression, while other studies showed no significant associations between ER or PR expression and prognosis[@b10][@b11][@b25]. Moreover, most studies combined all of the disease subtypes regardless of heterogeneity and had small sample sizes. This may hinder efforts to identify the subtype-specific significance of hormone receptor expression.

Sieh *et al.*[@b9] first evaluated the prognostic effects of ER and PR expression according to histological subtypes. Their study showed that ER or PR was positive in the majority of HGSCs and endometroid ovarian carcinomas, while their expression was rare in clear cell or mucinous carcinomas. In the histological subgroup analyses, ER and PR expression were associated with improved survival in endometroid ovarian carcinoma, and PR expression was associated with better survival in HGSC. Our study focused on only one histological type HGSC, which is the most common subtype of epithelial ovarian cancer and has high expression levels of hormone receptors. In contrast to Sieh's study, we used a cutoff value of 10% instead of 1% for ER− and PR−positive expression[@b19]. Studies of 875 HGSC patients show that ER expression is correlated with worse PFS and OS independently, while PR is only associated with improved PFS, but not OS. Our findings provide more information about the clinical significance of ER or PR expression in HGSC.

In addition, our study includes another promising biomarker, androgen receptor, which is seldom mentioned in ovarian cancer research[@b4][@b7][@b12][@b14]. Recent studies have highlighted androgen receptor as a promising prognostic and treatment-predictive marker of breast cancer[@b26][@b27]. Jonsson *et al.*[@b12] demonstrated a favorable outcome for ovarian cancer patients whose tumors coexpressed PR and AR. Our study, for the first time, suggests that AR is an independent predictor of platinum sensitivity in HGSC and improved OS. The underlying mechanism of their relationship should be studied in the future.

Consequently, our study has provided us with the possibility to establish a molecular classification of HGSC based on hormone receptor expression. As another type of hormone-related cancers, breast cancers are classified into four subtypes based on corresponding ER, PR, HER2 and Ki67 expression levels[@b28]. Similar attempts have been made to stratify ovarian cancer according to ER, PR and HER2 expression, but no significant clinicopathological differences were observed between the subgroups[@b29]. According to previous studies, the frequencies of HER2 overexpression in ovarian cancer varied[@b30]. Possible explanations might be the use of different antibodies as well as variable scoring systems. We selected the Roche antibody identified by the FDA for the HER2 test and evaluated HER2 expression according to the ASCO/CAP guideline[@b23]. Our study indicates that HER2 overexpression is rare in HGSC, and thus the potential application of HER2 in HGSC classification is limited.

Based on our results, we classified HGSC patients into five subgroups according to ER, PR and AR expression. Kruchten *et al.*[@b7] had also classified ovarian cancer according to ER, PR and AR expression. However, they combined all histological subtypes and did not refer to the hypothalamic-pituitary-gonadal axis-related hormone receptors. Our study included only patients diagnosed with HGSC, which excludes histological heterogeneity and allows for the identification of reliable and meaningful subgroups. Additionally, further investigation revealed that these groups have distinctive clinic-pathological characteristics. Only a small proportion of patients (4.3%) were PR − ER − AR+, which indicates a greater response to chemotherapy and improved OS. The proportion of the PR − ER + AR− subgroup ranked first (32.5%) in HGSC, and the prognosis of this group was the worst. Thus, those patients with worse prognosis might need more aggressive treatment and might require more frequent follow-up.

Our classifications indicate that we can predict patients' clinical outcomes by routine assessment of ER, PR and AR expression. This could help guide individual treatment and stratification of patients in future clinical trials. Hormone therapy has long been an alternative therapy for breast cancer[@b31]. However, hormone therapy has only been regarded as a salvage therapy for ovarian cancer. Previous studies have shown that the effect of endocrine therapy could be influenced by hormone receptor status with subgroup heterogeneity[@b32][@b33][@b34][@b35]. Our hormone receptor-based classification might be used in the selection of potential patients for endocrine therapy in future studies.

Moreover, though not included in the molecular classification of HGSC, our investigations on other biomarkers provide us with more information about future precise treatments for HGSC patients. The data on FSHR, LHR, and GnRHR expression were scarce in previous studies, and our study found high expression levels of FSHR, LHR and GnRHR. This suggests the possibility of using corresponding ligands as targeting moieties[@b36][@b37]. For instance, Zhang *et al.*[@b36] have developed a paclitaxel-loaded FSH binding peptide-targeted drug against ovarian cancer. Their *in vitro* and *in vivo* studies showed that this drug displays higher anti-tumor efficacy against FSHR-expressing tumors with less cytotoxicity. A phase II study of AEZ-108 (an LHRH agonist linked to doxorubicin) in LHRH-positive refractory ovarian cancer patients has been conducted[@b37]. Among treated patients, 14.3% (6/42) showed partial response and 38% (16/42) still had stable disease with a median PFS of 12 weeks and a median OS of 53 weeks. However, rare HER2 overexpression indicates the limited application potential of trastuzumab in HGSC.

In conclusion, for our study, we recruited a group of patients with the same histology who were treated within 9 years and underwent similar treatment procedures. We proposed an effective and clinically applicable classification of HGSC in light of our discovery. Indeed, it should also be further verified in an independent external cohort, and we think that a multicenter prospective cohort is preferred for this purpose. Furthermore, the underlying molecular pathogenesis mechanism of distinct subgroups should also be studied in the future. Although further investigations are necessary, our hormone receptor-based classification could help guide individual treatments and stratify patients in future studies.
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###### Characteristics of patients and hormone receptor expression (n = 875).

  ------------------------------------------- ------------------------------ ----- -----
  Age at diagnosis, median (range), years              56 (30--90)                 
  Follow-up time, median (range), months                29(1--115)                 
  Progression-free survival                    2-year: 38.1%, 5-year: 19.4%        
  Overall survival                             2-year: 79.3%, 5-year: 48.8%        
  Menopausal status                                   Postmenopausal          602   69%
  Premenopausal                                            273                31%  
  Family history (breast or ovarian cancer)                Yes                85    10%
  No                                                       790                90%  
  ECOG                                                      0                 512   59%
  1                                                        298                34%  
  2                                                         65                7%   
  FIGO                                              Early (FIGO I, II)        75    9%
  Advanced (FIGO III, IV)                                  800                91%  
  Residual Disease                                          R0                272   31%
  RD                                                       603                69%  
  Platinum sensitivity                                     Yes                568   67%
  No                                                       237                28%  
  NA                                                        44                5%   
  ER                                                 Positive (\>10%)         556   64%
  Negative (≤10%)                                          307                36%  
  PR                                                 Positive (\>10%)         109   13%
  Negative (≤10%)                                          755                87%  
  AR                                                 Positive (\>10%)         309   36%
  Negative (≤10%)                                          559                64%  
  FSHR                                              Positive (IRS ≥ 3)        470   55%
  Negative (IRS \< 3)                                      393                46%  
  LHR                                               Positive (IRS ≥ 3)        301   35%
  Negative (IRS \< 3)                                      563                65%  
  GnRHR                                                  Negative             100   12%
  Weak                                                     175                20%  
  Moderate                                                 306                36%  
  Strong                                                   276                32%  
  HER2                                                      0                 833   96%
  ≥1                                                        31                4%   
  Ki67                                               Positive (\>50%)         223   26%
  Negative (≤50%)                                          644                74%  
  ------------------------------------------- ------------------------------ ----- -----

###### Association between receptor expression and platinum sensitivity.

              Platinum sensitivity   P value              
  ---------- ---------------------- --------- ----- ----- -------
  ER                Positive           514     365   149   0.685
  71.0%              29.0%                                
  Negative            280              195     85         
  69.6%              30.4%                                
  PR                Positive           102     82    20    0.020
  80.4%              19.6%                                
  Negative            692              478     214        
  69.1%              30.9%                                
  AR                Positive           290     221   69    0.010
  76.2%              23.8%                                
  Negative            508              342     166        
  67.3%              32.7%                                
  FSHR              Positive           431     303   128   0.938
  70.3%              29.7%                                
  Negative            363              257     106        
  70.8%              29.2%                                
  LHR               Positive           276     198   78    0.682
  71.7%              28.3%                                
  Negative            518              363     155        
  70.1%              29.9%                                
  GnRHR             Positive           700     494   206   0.902
  70.6%              29.4%                                
  Negative             89              62      27         
  69.7%              30.3%                                
  HER2                 0               767     539   228   0.831
  70.3%              29.7%                                
  ≥1                   27              20       7         
  74.1%              25.9%                                
  Ki67              Positive           206     159   47    0.016
  77.2%              22.8%                                
  Negative            591              403     188        
  68.2%              31.8%                                

###### Univariate and multivariate analyses of factors associated with PFS and OS[1](#t3-fn1){ref-type="fn"}.

  Parameters            PFS              OS                                                                                                                
  ------------------ --------- ---------------------- ------- ------- ---- ------- --------- --------- ---------------------- ------- ------- ---- ------- ---------
  Age                   --      Continuous Variable    0.997   0.988   --   1.007    0.576      --      Continuous Variable    1.016   1.005   --   1.028  0.006
  FIGO Stage          \<0.001   Advanced *vs.* Early   2.413   1.577   --   3.691   \<0.001   \<0.001   Advanced *vs.* Early   3.618   1.728   --   7.576  0.001
  Residual Disease    \<0.001       RD *vs.* R0        1.633   1.324   --   2.015   \<0.001   \<0.001       RD *vs.* R0        1.958   1.457   --   2.631  \<0.001
  ER                   0.036          Negative         1.302   1.077   --   1.573    0.006     0.150          Negative         1.288   1.014   --   1.636  0.038
  PR                   0.009          Negative         0.718   0.538   --   0.958    0.024     0.061          Negative         0.911   0.617   --   1.346  0.641
  AR                   0.368          Negative         0.982   0.813   --   1.185    0.847     0.023          Negative         0.744   0.578   --   0.959  0.022
  FSHR                 0.975          Negative         1.024   0.862   --   1.217    0.786     0.586          Negative         1.166   0.936   --   1.451  0.171
  LHR                  0.455          Negative         1.108   0.925   --   1.329    0.266     0.782          Negative         0.971   0.772   --   1.222  0.805
  GnRHR                0.800          Negative         0.907   0.691   --   1.192    0.484     0.488          Negative         0.976   0.693   --   1.374  0.889
  HER2                 0.746             0             0.916   0.576   --   1.457    0.710     0.815             0             0.747   0.407   --   1.373  0.348
  Ki67                 0.021          Negative         0.835   0.683   --   1.021    0.079     0.003          Negative         0.688   0.520   --   0.910  0.009

^1^Numbers of patients (number of events/patients at risk): PFS (549/749), OS (345/875).

^2^Log-rank tests.

^3^Cox regression analysis expressed as hazard ratios.

###### Characteristics of patients within subgroups.

                  Parameters                     PR − ER − AR+         PR+       PR − ER + AR+   PR − ER − AR−   PR − ER + AR−   P value                                          
  ------------------------------------------- -------------------- ------------ --------------- --------------- --------------- --------- ------- ------- ------- ------- ------- ---------
    Age at diagnosis, median (range), years        56(37--79)       50(31--90)    56(36--81)      55(30--82)      57(34--84)     \<0.001                                          
               Menopausal status                 Postmenopausal         23           63.9%            45             46.9%         131     70.1%    166    66.9%    211    77.3%   \<0.001
                 Premenopausal                         13             36.1%           51             53.1%            56          29.9%     82     33.1%    62     22.7%          
   Family history (breast or ovarian cancer)          Yes               3            8.3%             12             12.5%         20      10.7%    16     6.5%     30     11.0%    0.322
                      No                               33             91.7%           84             87.5%            167         89.3%     232    93.5%    243    89.0%          
                     ECOG                              0                26           72.2%            66             68.8%         109     58.3%    146    58.9%    154    56.4%    0.117
                       1                               5              13.9%           25             26.0%            63          33.7%     87     35.1%    99     36.3%          
                       2                               5              13.9%            5             5.2%             15          8.0%      15     6.0%     20     7.3%           
                     FIGO                      Early (FIGO I, II)       4            11.1%            16             16.7%         15      8.0%     22     8.9%     15     5.5%     0.020
            Advanced (FIGO III, IV)                    32             88.9%           80             83.3%            172         92.0%     226    91.1%    258    94.5%          
               Residual Disease                        R0               12           33.3%            37             38.5%         58      31.0%    70     28.2%    85     31.1%    0.476
                      RD                               24             66.7%           59             61.5%            129         69.0%     178    71.8%    188    68.9%          
             Platinum sensitivity                     Yes               31           86.1%            71             76.3%         131     71.6%    149    62.6%    166    62.6%    0.034
                      No                               5              13.9%           19             20.4%            45          24.6%     74     31.1%    82     30.9%          
                      NA                               0               0.0%            3             3.2%              7          3.8%      15     6.3%     17     6.4%           

###### Risk of death in patients with HGSC depending on subgroup classification.

  Subgroup          N     \%     Overall death       Trend test        Overall survival                             
  --------------- ----- ------- --------------- --------------------- ------------------ ---------- ------- ------- -------
  PR − ER − AR+    36    4.3%      7(19.4%)            \<0.001              16.140        Referent    --     97.1%   67.4%
  PR+              96    11.4%     28(29.2%)     2.256(0.983--5.175)        0.055          87.3%     51.5%          
  PR − ER + AR+    187   22.3%     68(36.4%)     2.188(1.004--4.796)        0.049          83.7%     49.6%          
  PR − ER − AR−    248   29.5%    103(41.5%)     2.316(1.097--5.082)        0.028          77.7%     51.8%          
  PR − ER + AR−    273   32.5%    126(46.2%)     2.928(1.366--6.276)        0.006          75.1%     42.1%          

[^1]: These authors contributed equally to this work.
